VBI-2902
From Wikipedia, the free encyclopedia
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Other names | VBI-2902a |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[2]
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[3] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[3] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[3][4][5] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[6]
References
- ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ↑ Philippidis A (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.
- 1 2 3 "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. 9 March 2021. Retrieved 22 March 2021.
- ↑ "VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 March 2022.
- ↑ VBI Vaccines Inc. (1 October 2021). "A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults".
{{cite journal}}: Cite journal requires|journal=(help) - ↑ Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Archived from the original on 2 May 2021. Retrieved 22 March 2021.
External links
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |